Asset profile
PUR1900
Unknown / undisclosed
Evidence outlook · program status
On hold, as a strategic decision by the sponsor
PUR1900 is Pulmatrix's iSPERSE inhaled itraconazole for allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Pulmatrix's FY2025 Form 10-K, filed 2026-02-26, states that in connection with its merger it has paused development of its clinical candidates and is exploring monetisation; the same filing records that PUR1900 development is on hold in the US while partner Cipla advances the compound in India. Not discontinued: the asset is held for out-licensing and progresses under the partner. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.